title: VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer.
abstract: Angiogenesis inhibitors that block VEGF receptor (VEGFR) signaling slow the growth of many types of tumors, but eventually the disease progresses. Multiple strategies are being explored to improve efficacy by concurrent inhibition of other functionally relevant receptor tyrosine kinases (RTK). XL880 (foretinib, GSK1363089) and XL184 (cabozantinib) are small-molecule inhibitors that potently block multiple RTKs, including VEGFR and the receptor of hepatocyte growth factor c-Met, which can drive tumor invasion and metastasis. This study compared the cellular effects of XL880 and XL184 with those of an RTK inhibitor (XL999) that blocks VEGFR but not c-Met. Treatment of RIP-Tag2 mice with XL999 resulted in 43% reduction in vascularity of spontaneous pancreatic islet tumors over 7 days, but treatment with XL880 or XL184 eliminated approximately 80% of the tumor vasculature, reduced pericytes and empty basement membrane sleeves, caused widespread intratumoral hypoxia and tumor cell apoptosis, and slowed regrowth of the tumor vasculature after drug withdrawal. Importantly, XL880 and XL184 also decreased invasiveness of primary tumors and reduced metastasis. Overall, these findings indicate that inhibition of c-Met and functionally related kinases amplifies the effects of VEGFR blockade and leads to rapid, robust, and progressive regression of tumor vasculature, increased intratumoral hypoxia and apoptosis, and reduced tumor invasiveness and metastasis.
authors: Cardiovascular Research Institute, Comprehensive Cancer Center, and Department of Anatomy, University of California, San Francisco, CA 94143, USA.
authors: Weon-Kyoo
authors: WK
authors: You
authors: Barbara
authors: B
authors: Sennino
authors: Casey W
authors: CW
authors: Williamson
authors: Beverly
authors: B
authors: Falcón
authors: Hiroya
authors: H
authors: Hashizume
authors: Li-Chin
authors: LC
authors: Yao
authors: Dana T
authors: DT
authors: Aftab
authors: Donald M
authors: DM
authors: McDonald
references: Nature. 2009 Apr 9;458(7239):686-7
references: 19360048
references: Cancer Res. 2003 Nov 1;63(21):7345-55
references: 14612533
references: Cancer Res. 2009 Sep 1;69(17):6871-8
references: 19671800
references: Nat Rev Cancer. 2008 Aug;8(8):592-603
references: 18650835
references: Cancer Cell. 2009 Mar 3;15(3):220-31
references: 19249680
references: Adv Exp Med Biol. 2008;610:43-53
references: 18593014
references: Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
references: 18093943
references: Eur J Cancer. 2010 May;46(7):1260-70
references: 20303741
references: Nature. 1985 May 9-15;315(6015):115-22
references: 2986015
references: Oncogene. 2010 Sep 23;29(38):5254-64
references: 20603615
references: Nat Rev Mol Cell Biol. 2003 Dec;4(12):915-25
references: 14685170
references: Cancer Cell. 2009 Mar 3;15(3):167-70
references: 19249675
references: Cancer Res. 2006 Feb 1;66(3):1434-45
references: 16452199
references: Am J Pathol. 2004 Jul;165(1):35-52
references: 15215160
references: Nat Rev Drug Discov. 2006 Oct;5(10):835-44
references: 17016424
references: Cancer Cell. 2009 Mar 3;15(3):232-9
references: 19249681
references: Proc Natl Acad Sci U S A. 2010 Jan 19;107(3):1124-9
references: 20080645
references: Circ Res. 2004 Apr 16;94(7):984-92
references: 15001532
references: Nat Cell Biol. 2000 Oct;2(10):737-44
references: 11025665
references: Oncol Rep. 1998 Sep-Oct;5(5):1013-24
references: 9683803
references: Clin Cancer Res. 2007 Mar 1;13(5):1367-73
references: 17332278
references: Gastroenterology. 2009 Jul;137(1):361-71, 371.e1-5
references: 19362090
references: Cancer Res. 2000 Dec 1;60(23):6737-43
references: 11118060
references: Oncologist. 2007 Jan;12(1):107-13
references: 17227905
references: Oncogene. 2009 Oct 1;28(39):3442-55
references: 19633687
references: Oncologist. 2007 Jun;12(6):713-8
references: 17602060
references: Cancer Cell. 2004 May;5(5):443-53
references: 15144952
references: Cancer Cell. 2008 Mar;13(3):206-20
references: 18328425
references: Cancer Res. 2010 Feb 15;70(4):1544-54
references: 20145120
references: J Cell Biol. 1992 Nov;119(3):629-41
references: 1383237
references: Nat Med. 2001 Sep;7(9):987-9
references: 11533692
references: Eur J Cancer. 2006 Jul;42(10):1351-6
references: 16740386
references: Cancer Res. 2009 Oct 15;69(20):8009-16
references: 19808973
references: Cancer Cell. 2003 Apr;3(4):347-61
references: 12726861
references: Nat Med. 1998 Mar;4(3):336-40
references: 9500609
references: Cancer Cell. 2005 Oct;8(4):299-309
references: 16226705
references: Nature. 2003 Jun 5;423(6940):593-5
references: 12789320
references: Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H560-76
references: 16172168
references: Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6144-52
references: 17062691
references: Am J Physiol Heart Circ Physiol. 2006 Feb;290(2):H547-59
references: 16172161
references: Cancer Res. 2000 Sep 15;60(18):5117-24
references: 11016638
references: J Clin Invest. 2006 Oct;116(10):2610-21
references: 17016557
references: Cancer Cell. 2004 Jul;6(1):61-73
references: 15261142
references: Nature. 2005 Dec 15;438(7070):967-74
references: 16355214
references: J Cell Physiol. 2007 Nov;213(2):316-25
references: 17607709